

Pulmonary Vein Isolation (PVI) as First-Line Therapy for Atrial Fibrillation (AF): AQUA Heart leads the way

Study shows first-line ablation therapy's significant benefits for Atrial Fibrillation. AQUA Heart's PVI innovation offers transformation in AF treatment

SANTA ANA, CA, USA, October 30, 2023

[/EINPresswire.com/](https://www.einpresswire.com/) -- In a study conducted by author Jason D. Andrade et al., the debate over first-line therapy for Atrial Fibrillation (AF) received a resounding answer. The study, recently published, compared first-line ablation therapy with Antiarrhythmic Drug Therapy (AAD), delivering promising results that could transform the landscape of AF treatment.

The authors' findings are unequivocal: "Ablation as a first-line therapy for AF is associated with significant reductions in arrhythmia recurrence, substantial improvements in arrhythmia-related symptoms and quality of life, and lower rates of adverse events. In addition, catheter ablation is associated with significantly lower rates of disease progression, suggesting that it is a disease-modifying intervention."



This research underscores the potential of first-line ablation therapy as a game-changer in AF treatment,"

Dr. Holger Friedrich

The logo for AQUAHeart, with the word "AQUAHeart" in a large, black, sans-serif font. The "A" is significantly larger than the other letters, and there is a registered trademark symbol (®) to the upper right of the "t".

Restoring Rhythm

AQUA Heart - Restoring Rhythm

(Source:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398511/>)

What's particularly notable is that these conclusions extend to younger patients with both chronic and non-persistent Atrial Fibrillation (AF or AFib), offering hope for a broader spectrum of individuals seeking effective

treatment options.

The preferred first-line ablation therapy highlighted in this research is Pulmonary Vein Isolation (PVI).

[AQUA Heart](#), a pioneering MedTech company spearheading the development of the fastest, easiest, safest, and most efficient system for performing PVI. Their groundbreaking technology is set to revolutionize AF therapy by democratizing access to this transformative treatment.

"This research underscores the potential of first-line ablation therapy as a game-changer in AF treatment," said Dr. Holger Friedrich, CEO of AQUA Heart Inc.. "We're on a mission to make PVI even more accessible, efficient, and effective. With our innovative approach, we aim to empower healthcare professionals and offer hope to countless individuals battling AF."

The implications of this research are profound. By embracing first-line ablation therapy, the medical community is taking a significant step toward enhancing the quality of life for AF patients and potentially altering the course of the disease. AQUA Heart's commitment to advancing PVI technology aligns perfectly with this vision, and they're poised to lead the charge in transforming the future of AF therapy.

For more information about AquaHeart and their groundbreaking technology, please visit <https://www.aquahrt.com> for more information or follow us on [LinkedIn](https://www.linkedin.com/company/aqua-heart-inc) <https://www.linkedin.com/company/aqua-heart-inc>

Dr. Holger Friedrich
Aqua Heart Inc.
ir@aquahrt.com

Visit us on social media:
[LinkedIn](#)

AQUAHeart®

AQUA Heart - Restoring Rhythm



AQUA Heart - Award winning technology

This press release can be viewed online at: <https://www.einpresswire.com/article/662601674>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.